Celli C M, Gharavi A E
Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Brasil.
Braz J Med Biol Res. 1998 Jun;31(6):723-32. doi: 10.1590/s0100-879x1998000600002.
Antiphospholipid antibodies (aPL) are a heterogeneous group of antibodies that are detected in the serum of patients with a variety of conditions, including autoimmune (systemic lupus erythematosus), infectious (syphilis, AIDS) and lymphoproliferative disorders (paraproteinemia, myeloma, lymphocytic leukemias). Thrombosis, thrombocytopenia, recurrent fetal loss and other clinical complications are currently associated with a subgroup of aPL designating the antiphospholipid syndrome. In contrast, aPL from patients with infectious disorders are not associated with any clinical manifestation. These findings led to increased interest in the origin and pathogenesis of aPL. Here we present the clinical features of the antiphospholipid syndrome and review the origin of aPL, the characteristics of experimentally induced aPL and their historical background. Within this context, we discuss the most probable pathogenic mechanisms induced by these antibodies.
抗磷脂抗体(aPL)是一类异质性抗体,在多种疾病患者的血清中均可检测到,这些疾病包括自身免疫性疾病(系统性红斑狼疮)、感染性疾病(梅毒、艾滋病)和淋巴增殖性疾病(副蛋白血症、骨髓瘤、淋巴细胞白血病)。目前,血栓形成、血小板减少、复发性流产及其他临床并发症与抗磷脂综合征这一aPL亚组相关。相比之下,感染性疾病患者的aPL与任何临床表现均无关联。这些发现引发了人们对aPL起源及发病机制的更多关注。在此,我们介绍抗磷脂综合征的临床特征,并综述aPL的起源、实验诱导产生的aPL的特点及其历史背景。在此背景下,我们讨论这些抗体最可能的致病机制。